AGIOS PHARMACEUTICALS, INC. - 8-K Filing
Agios Pharmaceuticals reported Q2 net revenue of $44.7M from mitapivat, with FDA Priority Review for sickle cell disease sNDA and licensing of cevidoplenib.
Tickers: $AGIO
More Regulatory news
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing
- RF Acquisition Corp II - 10-Q Filing
- ORASURE TECHNOLOGIES INC - 10-Q Filing
- Rocket Companies, Inc. - 8-K Filing
- Applied Aerospace & Defense, Inc. - 10-Q Filing
- Palomar Holdings, Inc. - 8-K Filing
- UNITED GUARDIAN INC - 10-Q Filing